Skip to main content
SpringerLink
Log in

Prazosin in Chronic Heart Failure

  • Chapter
Acute and Chronic Heart Failure

  • 85 Accesses

Abstract

Since 1974, prazosin has been available as an antihypertensive agent but has only recently become widely adopted into clinical practice (Cotton 1974) (Fig. 149). There were initial uncertainties regarding the mechanism of action. The ‘first dose’ phenomenon, that is, the occasionally observed orthostatic collapse after administration of an initial dose of 2 mg or more was another reason for slow acceptance of this agent into clinical use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature

  • Ahlquist RP (1948) A study of the adrenergic receptors. Am J Physiol 153: 586–600

    PubMed  CAS  Google Scholar 

  • Arnold SB, Williams RL, Pots TA, Baughman RA, Benot LZ, Parmley WW, Chatterjee K (1979) Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med 91: 345–349

    PubMed  CAS  Google Scholar 

  • Aronow WS, Danahy DT (1978) Efficacy of trimazosin and prazosin therapy on cardiac and exercise performance in outpatients with chronic congestive heart failure. Am J Med 65: 155–160

    Article  PubMed  CAS  Google Scholar 

  • Aronow WS, Lurie M, Turbow M, Whittaker K, Van Camp S, Hughes D (1979) Effect of prazosin vs placebo on chronic left ventricular heart failure. Circulation 59: 344–350

    PubMed  CAS  Google Scholar 

  • Awan NA, Mason DT (1981) Oral vasodilator therapy with prazosin in severe congestive heart failure. Am Heart J 101: 695–700

    Article  PubMed  CAS  Google Scholar 

  • Awan NA, Miller RR, DeMaria AN, Maxwell KS, Neumann A, Mason DT (1977) Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Circulation 56: 346–354

    PubMed  CAS  Google Scholar 

  • Awan NA, Miller RR, Mason DT (1978 a) Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure. Circulation 57: 152–159

    Google Scholar 

  • Awan NA, Miller RR, Miller MP, Specht K, Vera Z, Mason DT (1978 b) Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Am J Med 65: 146–154

    Google Scholar 

  • Awan NA, Lee G, DeMaria AN, Mason DT (1981) Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. Am Heart J 101: 541–547

    Article  PubMed  CAS  Google Scholar 

  • Bertel O, Burkhard F (1981) Langzeitresultate der Vasodilatator-Therapie mit Prazosin bei therapierefraktärer schwerer Herzinsuffizienz. Ther Umsch 38: 45–48

    PubMed  Google Scholar 

  • Burkard F, Bertel O (1983) Prazosin therapy in severe chronic congestive heart failure. In: Just H, Bussmann WD (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 139–146

    Chapter  Google Scholar 

  • Colucci WS, Wynne J, Holman BL, Braunwald E (1980) Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol 45: 337–344

    Article  PubMed  CAS  Google Scholar 

  • Constantine JW, McShane WK, Scriabine A, Hess HJ (1973) Analysis of the hypotensive action of prazosin. In: Onesti G, Kim KE, Moyer JH (eds) Hypotension: Mechanisms and management. Grune & Stratton, New York, pp 429–444

    Google Scholar 

  • Cotton DWK (ed) (1974) Prazosin: Evaluation of a new antihypertensive agent. Excerpta Medica, Geneva

    Google Scholar 

  • Elkayam V, LeJemtel TH, Mathur M, Ribner HS, Frishman WH, Strom J, Sonnenblick EH (1979) Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol 44: 540–545

    Article  PubMed  CAS  Google Scholar 

  • Feldmann AC, Ball AM, Winchester MA, Jaillon P, Kates RE, Harrison DC (1981) Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure. Am Heart J 101: 534–540

    Article  Google Scholar 

  • Graham RM, Thorneil IR, Gain JM, Bagnoli C, Oates HF, Stokes GS (1976) Prazosin: the first-dose phenomenon. Br Med J II: 1293–1294

    Google Scholar 

  • Hepp A, Schick KD, Larbig D, Haasis R, Liebau G, Riegger G, Kochsiek K (1980) Uneinheitliche Wirkung von Prazosin auf die Linksherzinsuffizienz im akuten Versuch. Dtsch Med Wochenschr 105: 1647–1650

    Article  PubMed  CAS  Google Scholar 

  • Himmler FC, Wirtzfeld A, Klein G, Volger E, Schmidt G (1980) Hämodynamische Wirkung von Prazosin bei Patienten mit schwerer Herzinsuffizienz. Herz Kreislauf 12: 317–322

    Google Scholar 

  • Hobbs DC, Twomey TM, Palmer RF (1978) Pharmacokinetics of prazosin in man. J Clin Pharmacol 18: 402–206

    PubMed  CAS  Google Scholar 

  • Kersting F, Samosny G, Kasper W, Meinertz T, Gilfrich HJ, Just H (1980) Clinical pharmacology of prazosin and phentolamine in patients with heart failure. J Cardiovasc Pharmacol [Suppl] 2: 373

    Google Scholar 

  • Kuck KH, Hanrath P, Zehnke A, Mathey D, Bleifeld W ( 1980 a) Prazosin — Langzeitbehandlung der schweren chronischen Herzinsuffizienz, Wirkung auf die Ruhe- und Belastungshämodynamik. Dtsch Med Wochenschr 105: 1384–1388

    Google Scholar 

  • Kuck KH, Hanrath P, Zehnke A, Mathey D, Bleifeld W (1980 b) Hemodynamic effects of long-term prazosin therapy in patients with congestive heart failure. J Cardiovasc Pharmacol [Suppl 3] 2: 427–441

    Google Scholar 

  • Kuhn H, Bock H, Lösse B (1981) Wirkung einer chronischen Verabreichung von Prazosin mit kongestiver Kardiomyopathie. Z Kardiol 70: 501–507

    PubMed  CAS  Google Scholar 

  • Lemke R, Trompler A, Kaltenbach M, Bussmann WD (1979) Wirkung von Prazosin bei der therapierefraktären chronischen Herzinsuffizienz. Dtsch Med Wochenschr 104: 1769–1773

    Article  PubMed  CAS  Google Scholar 

  • Lemke R, Trompler A, Kaltenbach M, Bussmann WD (1981) Controlled study of long-term prazosin in refractory heart failure. Eur Heart J 2: 211–216

    PubMed  CAS  Google Scholar 

  • Machow P, Vatner SF (1982) Effects of prazosin on coronary and left ventricular dynamics in conscious dogs. Circulation 65: 1186–1192

    Article  Google Scholar 

  • Mehta J, Miles D, Iacona M, Conti CR (1981) Long-term maintenance therapy with prazosin in congestive heart failure. Clin Cardiol 4: 139–145

    Article  PubMed  CAS  Google Scholar 

  • Moulds RFW, Jauernig RA (1977) Mechanism of prazosin collapse. Lancet I: 200–201

    Google Scholar 

  • Packer M, Meiler J, Gorlin R, Herman MW (1979) Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59: 531–539

    PubMed  CAS  Google Scholar 

  • Reifart M, Schmidt-Moritz AD, Nadj M, Kaltenbach M, Bussmann WD (1983) Langzeittherapie mit Prazosin bei chronischer Herzinsuffizienz. Randomisierte Doppelblind-Studie (Abstract). Z Kardiol [Suppl 1] 72: 84

    Google Scholar 

  • Rubin SA, Chatterjee K, Gelberg HJ, Ports TA, Brundage BH, Parmley WW (1979) Paradox of improved exercise but not resting hemodynamic with short-term prazosin in chronic heart failure. Am J Cardiol 43: 810–815

    Article  PubMed  CAS  Google Scholar 

  • Starke K (1977) Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 77: 1–124

    Article  PubMed  CAS  Google Scholar 

  • Starke K (1981) Prazosin — Pharmakologie und Wirkmechanismus. Ther Umsch 38: 24–27

    PubMed  Google Scholar 

  • Taylor JA, Twomey TM, Schach von Wittenau M (1977) The metabolic fate of prazosin. Xenobiotica 7: 357–364

    Article  PubMed  CAS  Google Scholar 

  • Wirtzfeld A, Klein G, Himmler FC, Schmidt G, Kutschera I, Sauer E (1980) Oral wirksame Vasodilatator bei der chronischen therapieresistenten Herzinsuffizienz. Wirkungsvergleich von Isosorbiddinitrat, Prazosin und Dihydralazin. Dtsch Med Wochenschr 105: 1379–1383

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-6000, Frankfurt 70, Germany

    Professor Dr. med. Wulf-Dirk Bussmann

Authors
  1. Professor Dr. med. Wulf-Dirk Bussmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bussmann, WD. (1986). Prazosin in Chronic Heart Failure. In: Acute and Chronic Heart Failure. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61627-3_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-61627-3_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64890-8

  • Online ISBN: 978-3-642-61627-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation